Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EquiTech Corporation has provided further evidence to support the efficacy of its novel reformulated ibuprofen caplet, ZAG-1701, as the drug has beaten a rival Johnson and Johnson product in a phase II trial.
Subscribe to our email newsletter
The primary objective of the phase II clinical trial was to compare the speed of absorption of ibuprofen into the bloodstream of a 400mg dose of ZAG-1701 with a 400mg dose of Johnson & Johnson’s Motrin IB in patients experiencing the pain of wisdom tooth extraction.
Further details of the trial have now been released following a review of the trial results.
The data from the clinical study revealed that at 15 minutes after drug dosing, almost three times more ibuprofen entered the blood stream in patients who took ZAG-1701 compared to patients who took Motrin IB.
Statistically significant increased absorption was also observed at 30 minutes where 2.7 times, at 45 minutes where 2.3 times, and at 60 minutes where two times more ibuprofen entered the blood stream in patients given ZAG-1701 compared to patients who took Motrin IB.
The data also showed that in patients who received ZAG-1701 caplets, peak concentrations of ibuprofen in the blood stream occurred on average at one hour and 26 minutes compared to two hours and 19 minutes for Motrin IB.
“These results suggest that, during the first hour and half after drug administration, when the analgesic effect is most desired, the drug enters the bloodstream up to 2.8 times more following ZAG-1701 as compared with Motrin IB,” said Dr Fakhreddin Jamali, chief scientific officer and scientific founder of EquiTech.
“The result of this study can be extrapolated to other acute pains because wisdom tooth removal is the accepted industry standard test to evaluate the effectiveness of pain relief products for general mild to moderate acute pain,” Jamali continued.